The midregional portion of proadrenomedullin is an independent predictor of left ventricular mass index in hypertension

Metabolism: Clinical and Experimental

Volumn 59, Issue 1, 2010, Pages 7-13

  Bhandari, Sanjay S ^a   Davies, Joan E ^a   Struck, Joachim ^b   Ng, Leong L ^a  

^a UNIVERSITY OF LEICESTER   (United Kingdom)

^b BRAHMS AG   (Germany)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; CALCIUM CHANNEL BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; PROADRENOMEDULLIN; THIAZIDE DIURETIC AGENT;

AGED; ARTICLE; CARDIOVASCULAR RISK; CONTROLLED STUDY; DIAGNOSTIC PROCEDURE; ECHOCARDIOGRAPHY; FEMALE; HEART LEFT VENTRICLE HYPERTROPHY; HEART LEFT VENTRICLE MASS; HUMAN; HYPERTENSION; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; SENSITIVITY AND SPECIFICITY; SEX DIFFERENCE;

ADRENOMEDULLIN; AGED; CARDIOMEGALY; ELECTROCARDIOGRAPHY; FEMALE; HEART VENTRICLES; HUMANS; HYPERTENSION; MALE; MIDDLE AGED; ORGAN SIZE; PROTEIN PRECURSORS;

EID: 72149083587     PISSN: 00260495     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.metabol.2009.06.019     Document Type: Article

References (44)

1. Weber K.T., Brilla C.G., Campbell S.E., Zhou G., Matsubara L., and Guarda E. Pathologic hypertrophy with fibrosis: the structural basis for myocardial failure. Blood Press 1 (1992) 75-85
2. Weber K.T., Sun Y., and Guarda E. Structural remodeling in hypertensive heart disease and the role of hormones. Hypertension 23 (1994) 869-877
3. Devereux R.B., de Simone G., Ganau A., and Roman M.J. Left ventricular hypertrophy and geometric remodeling in hypertension: stimuli, functional consequences and prognostic implications. J Hypertens Suppl 12 (1994) 117-127
4. Schmieder R.E., Martus P., and Klingbeil A. Reversal of left ventricular hypertrophy in essential hypertension. A meta-analysis of randomized double-blind studies. JAMA 275 (1996) 1507-1513
5. Devereux R.B., and Alderman M.H. Role of preclinical cardiovascular disease in the evolution from risk factor exposure to development of morbid events. Circulation 88 (1993) 1444-1455
6. Levy D., Garrison R.J., Savage D.D., Kannel W.B., and Castelli W.P. Prognostic implications of echocardiographically determined left ventricular mass in the Framingham Heart Study. N Engl J Med 322 (1990) 1561-1566
7. Levy D., Anderson K.M., Savage D.D., Kannel W.B., Christiansen J.C., and Castelli W.P. Echocardiographically detected left ventricular hypertrophy: prevalence and risk factors. The Framingham Heart Study. Ann Intern Med 108 (1988) 7-13
8. Pierdomenico S.D., Lapenna D., and Cuccurullo F. Regression of echocardiographic left ventricular hypertrophy after 2 years of therapy reduces cardiovascular risk in patients with essential hypertension. Am J Hypertens 21 (2008) 464-470
9. Okin P.M., Roman M.J., Devereux R.B., and Kligfield P. Time-voltage area of the QRS for the identification of left ventricular hypertrophy. Hypertension 27 (1996) 251-258
10. Cuspidi C., Meani S., Valerio C., Fusi V., Sala C., and Zanchetti A. Left ventricular hypertrophy and cardiovascular risk stratification: impact and cost-effectiveness of echocardiography in recently diagnosed essential hypertensives. J Hypertens 24 (2006) 1671-1677
11. McDonagh T.A., Robb S.D., Murdoch D.R., et al. Biochemical detection of left-ventricular systolic dysfunction. Lancet 351 (1998) 9-13
12. Yamamoto K., Burnett Jr. J.C., Jougasaki M., et al. Superiority of brain natriuretic peptide as a hormonal marker of ventricular systolic and diastolic dysfunction and ventricular hypertrophy. Hypertension 28 (1996) 988-994
13. Omland T., Aakvaag A., Bonarjee V.V., et al. Plasma brain natriuretic peptide as an indicator of left ventricular systolic function and long-term survival after acute myocardial infarction. Comparison with plasma atrial natriuretic peptide and N-terminal proatrial natriuretic peptide. Circulation 93 (1996) 1963-1969
14. Kohno M., Horio T., Yokokawa K., et al. Brain natriuretic peptide as a cardiac hormone in essential hypertension. Am J Med 92 (1992) 29-34
15. Cheung B.M. Plasma concentration of brain natriuretic peptide is related to diastolic function in hypertension. Clin Exp Pharmacol Physiol 24 (1997) 966-968
16. Nishikimi T., Yoshihara F., Morimoto A., et al. Relationship between left ventricular geometry and natriuretic peptide levels in essential hypertension. Hypertension 28 (1996) 22-30
17. Mouly-Bertin C., Bissery A., Milon H., et al. N-terminal pro-brain natriuretic peptide-a promising biomarker for the diagnosis of left ventricular hypertrophy in hypertensive women. Arch Cardiovasc Dis 101 (2008) 307-315
18. Nakamura M., Tanaka F., Yonezawa S., et al. The limited value of plasma B-type natriuretic peptide for screening for left ventricular hypertrophy among hypertensive patients. Am J Hypertens 16 (2003) 1025-1029
19. Cowie M.R., Jourdain P., Maisel A., et al. Clinical applications of B-type natriuretic peptide (BNP) testing. Eur Heart J 24 (2003) 1710-1718
20. Kitamura K., Kangawa K., Kawamoto M., et al. Adrenomedullin: a novel hypotensive peptide isolated from human pheochromocytoma. Biochem Biophys Res Commun 192 (1993) 553-560
21. Ichiki Y., Kitamura K., Kangawa K., Kawamoto M., Matsuo H., and Eto T. Distribution and characterization of immunoreactive adrenomedullin in human tissue and plasma. FEBS Lett 338 (1994) 6-10
22. Sugo S., Minamino N., Kangawa K., et al. Endothelial cells actively synthesize and secrete adrenomedullin. Biochem Biophys Res Commun 201 (1994) 1160-1166
23. Kitamura K., Sakata J., Kangawa K., Kojima M., Matsuo H., and Eto T. Cloning and characterization of cDNA encoding a precursor for human adrenomedullin. Biochem Biophys Res Commun 194 (1993) 720-725
24. Meeran K., O'Shea D., Upton P.D., et al. Circulating adrenomedullin does not regulate systemic blood pressure but increases plasma prolactin after intravenous infusion in humans: a pharmacokinetic study. J Clin Endocrinol Metab 82 (1997) 95-100
25. Hinson J.P., Kapas S., and Smith D.M. Adrenomedullin, a multifunctional regulatory peptide. Endocr Rev 21 (2000) 138-167
26. Nakamura M., Yoshida H., Makita S., Arakawa N., Niinuma H., and Hiramori K. Potent and long-lasting vasodilatory effects of adrenomedullin in humans. Comparisons between normal subjects and patients with chronic heart failure. Circulation 95 (1997) 1214-1221
27. Vari R.C., Adkins S.D., and Samson W.K. Renal effects of adrenomedullin in the rat. Proc Soc Exp Biol Med 211 (1996) 178-183
28. Parkes D.G., and May C.N. Direct cardiac and vascular actions of adrenomedullin in conscious sheep. Br J Pharmacol 120 (1997) 1179-1185
29. Kitamura K., Ichiki Y., Tanaka M., et al. Immunoreactive adrenomedullin in human plasma. FEBS Lett 341 (1994) 288-290
30. Khan S.Q., O'Brien R.J., Struck J., et al. Prognostic value of midregional pro-adrenomedullin in patients with acute myocardial infarction: the LAMP (Leicester Acute Myocardial Infarction Peptide) study. J Am Coll Cardiol 49 (2007) 1525-1532
31. Gegenhuber A., Struck J., Dieplinger B., et al. Comparative evaluation of B-type natriuretic peptide, mid-regional pro-A-type natriuretic peptide, mid-regional pro-adrenomedullin, and Copeptin to predict 1-year mortality in patients with acute destabilized heart failure. J Card Fail 13 (2007) 42-49
32. Stevens L.A., Coresh J., Feldman H.I., et al. Evaluation of the modification of diet in renal disease study equation in a large diverse population. J Am Soc Nephrol 18 (2007) 2749-2757
33. Sokolow M., and Lyon T.P. The ventricular complex in left ventricular hypertrophy as obtained by unipolar precordial and limb leads. Am Heart J 37 (1949) 161-186
34. Schiller N.B., Shah P.M., Crawford M., et al. Recommendations for quantitation of the left ventricle by two-dimensional echocardiography. American Society of Echocardiography Committee on Standards, Subcommittee on Quantitation of Two-Dimensional Echocardiograms. J Am Soc Echocardiogr 2 (1989) 358-367
35. Devereux R.B., Koren M.J., de Simone G., et al. Methods for detection of left ventricular hypertrophy: application to hypertensive heart disease. Eur Heart J 14 (1993) 8-15
36. Guidelines Subcommittee World Health Organization/International Society of Hypertension (WHO/ISH). Guidelines for the management of hypertension. J Hypertens 17 (1999) 151-183
37. Omland T., Persson A., Ng L., et al. N-terminal pro-B-type natriuretic peptide and long-term mortality in acute coronary syndromes. Circulation 106 (2002) 2913-2918
38. Morgenthaler N.G., Struck J., Alonso C., and Bergmann A. Measurement of midregional proadrenomedullin in plasma with an immunoluminometric assay. Clin Chem 51 (2005) 1823-1829
39. Redfield M.M., Rodeheffer R.J., Jacobsen S.J., et al. Plasma brain natriuretic peptide concentration: impact of age and gender. J Am Coll Cardiol 40 (2002) 976-982
40. Devereux R.B., and Roman M.J. Hypertensive cardiac hypertrophy: patho-physiologic and clinical characteristics. In: Laragh J.H., and Brenner B.M. (Eds). Hypertension: pathophysiology, diagnosis and management. 2nd ed (1995), Raven Press, New York 409-424
41. Sumimoto T., Nishikimi T., Mukai M., et al. Plasma adrenomedullin concentrations and cardiac and arterial hypertrophy in hypertension. Hypertension 30 (1997) 741-745
42. Belluardo P., Cataliotti A., Bonaiuto L., et al. Lack of activation of molecular forms of the BNP system in human grade 1 hypertension and relationship to cardiac hypertrophy. Am J Physiol Heart Circ Physiol 291 (2006) 1529-1535
43. Jougasaki M., Rodeheffer R.J., Redfield M.M., et al. Cardiac secretion of adrenomedullin in human heart failure. J Clin Invest 97 (1996) 2370-2376
44. Jougasaki M., Wei C.M., McKinley L.J., and Burnett Jr. J.C. Elevation of circulating and ventricular adrenomedullin in human congestive heart failure. Circulation 92 (1995) 286-289